Catalyst Pharmaceuticals
Desiree Hollandsworth has a diverse work experience spanning over 30 years. Desiree currently holds the position of Sr. Director, Commercial Operations and Marketing at Catalyst Pharmaceuticals since September 2018. Prior to this, they worked at Synchrony Group as a Senior Director, Account Services from September 2016 to September 2018.
From 2012 to 2016, Desiree worked at Insys Therapeutics, Inc. as an Associate Director, Medical Marketing Communications. Desiree was responsible for establishing and executing strategic communication plans, managing the speaker bureau, and coordinating various activities such as peer-to-peer education and sales training meetings.
Before joining Insys Therapeutics, Desiree worked at Synchrony Healthcare Group as a Director, Meeting and Logistic Services from August 2010 to November 2012. Desiree played a key role in launching meeting management offerings and identifying national and regional speakers for the client's first commercialized product.
Desiree's career in the pharmaceutical industry began at inVentiv Health, where they held various account services positions from April 1999 to August 2009. Desiree gained extensive experience in managing client projects, developing financial reports, and leading a team of planners.
Desiree'searlier work experience includes a role as Banquet Manager at SCIOTO COUNTRY CLUB from February 1998 to April 1999, and as Assistant Catering Manager at Kroger from June 1986 to February 1998.
Desiree Hollandsworth attended Patrick Henry High School from 1982 to 1986. After completing high school, Desiree pursued a Bachelor's degree in Hotel Restaurant Management at Virginia Polytechnic Institute and State University from 1986 to 1992.
This person is not in any offices
Catalyst Pharmaceuticals
2 followers
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.